Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add more filters










Publication year range
1.
Eur J Pharmacol ; 957: 175962, 2023 Oct 15.
Article in English | MEDLINE | ID: mdl-37544422

ABSTRACT

The sensing of self RNA by the endosomal Toll-like receptors (TLRs) 7 and 8 initiates pathogenic mechanisms underlying the autoimmune disease lupus. A blockade of the TLR7/8 signals may, therefore, be a novel therapeutic intervention for lupus. To test the hypothesis, a novel compound E6742 that blocks TLR7/8 activation was identified. The mode of action of E6742 was investigated by analysis of the tertiary structure of TLR7 and 8 in complex with E6742. The in vitro activities of the compound were examined in cellular systems and its therapeutic potential was evaluated in murine lupus models. Tertiary structures of the extracellular domain of TLR7 and 8 in complex with E6742 showed that E6742 binds specifically and non-covalently to the hydrophobic pocket located at the interface of TLR7 or TLR8 homodimers. E6742 potently and selectively inhibited several TLR7/8-mediated cytokine responses in human PBMC. In two mouse models of lupus, oral dosing of E6742 after the onset of disease suppressed increase in autoantibodies and blocked the advance of organ damage. Collectively, the data show that TLR7/8 activation contributes to disease progression and its blocking by E6742 has potential as a therapeutic intervention for lupus.


Subject(s)
Leukocytes, Mononuclear , Toll-Like Receptor 7 , Mice , Humans , Animals , Toll-Like Receptor 7/genetics , Toll-Like Receptor 7/metabolism , Disease Models, Animal , Leukocytes, Mononuclear/metabolism , Toll-Like Receptor 8/metabolism , Autoantibodies , Toll-Like Receptor 9
2.
J Immunol ; 209(10): 1950-1959, 2022 11 15.
Article in English | MEDLINE | ID: mdl-36426935

ABSTRACT

The mechanisms by which TLR4-based adjuvants enhance immunogenicity are not fully understood. We have taken advantage of a novel knock-in mouse strain that homozygously expresses two single-nucleotide polymorphisms (SNPs) that are homologous to human TLR4 (rs4986790 and rs4986791) and have been associated with LPS hyporesponsiveness in vivo and in vitro. TLR4-SNP (coexpressing mutations D298G/N397I in TLR4) mice that recapitulate the human phenotype were compared with wild-type (WT) mice for their hapten-specific Ab responses after immunization with hapten 4-hydroxy-3-nitrophenyl acetyl (NP) NP-Ficoll or NP-OVA in the absence or presence of a water-soluble TLR4 analog adjuvant, E6020. IgM and IgG anti-NP responses were comparable in WT and TLR4-SNP mice after immunization with either NP-Ficoll or NP-OVA only. E6020 significantly yet transiently improved the IgM and IgG anti-NP responses of both WT and TLR4-SNP mice to NP-Ficoll (T-independent), with modestly enhanced Ab production in WT mice. In contrast, T-dependent (NP-OVA), adjuvant-enhanced responses showed sustained elevation of NP-specific Ab titers in WT mice, intermediate responses in TLR4-SNP mice, and negligible enhancement in TLR4-/- mice. E6020-enhanced early humoral responses in WT and TLR4-SNP mice to NP-OVA favored an IgG1 response. After a second immunization, however, the immune responses of TLR4-SNP mice remained IgG1 dominant, whereas WT mice reimmunized with NP-OVA and E6020 exhibited increased anti-NP IgG2c titers and a sustained increase in the IgG1 and IgG2c production by splenocytes. These findings indicate that E6020 increases and sustains Ab titers and promotes isotype class switching, as evidenced by reduced titers and IgG1-dominant immune responses in mice with TLR4 insufficiency.


Subject(s)
Immunoglobulin Class Switching , Toll-Like Receptor 4 , Animals , Humans , Mice , Adjuvants, Immunologic , Ficoll , Haptens , Immunization , Immunoglobulin G , Immunoglobulin M , Toll-Like Receptor 4/genetics
3.
Vaccine ; 38(27): 4298-4308, 2020 06 02.
Article in English | MEDLINE | ID: mdl-32389496

ABSTRACT

Toll-like receptors (TLRs), a family of "pattern recognition receptors," bind microbial and host-derived molecules, leading to intracellular signaling and proinflammatory gene expression. TLR4 is unique in that ligand-mediated activation requires the co-receptor myeloid differentiation 2 (MD2) to initiate two signaling cascades: the MyD88-dependent pathway is initiated at the cell membrane, and elicits rapid MAP kinase and NF-κB activation, while the TIR-domain containing adaptor inducing interferon-ß (TRIF)-dependent pathway is initiated from TLR4-containing endosomes and results in IRF3 activation. Previous studies associated inflammation with the MyD88 pathway and adjuvanticity with the TRIF pathway. Gram-negative lipopolysaccharide (LPS) is a potent TLR4 agonist, and structurally related molecules signal through TLR4 to differing extents. Herein, we compared monophosphoryl lipid A (sMPL) and E6020, two synthetic, non-toxic LPS lipid A analogs used as vaccine adjuvants, for their capacities to activate TLR4-mediated innate immune responses and to enhance antibody production. In mouse macrophages, high dose sMPL activates MyD88-dependent signaling equivalently to E6020, while E6020 exhibits significantly more activation of the TRIF pathway (a "TRIF bias") than sMPL. Eritoran, a TLR4/MD2 antagonist, competitively inhibited sMPL more strongly than E6020. Despite these differences, sMPL and E6020 adjuvants enhanced antibody responses to comparable extents, with balanced immunoglobulin (Ig) isotypes in two immunization models. These data indicate that a TRIF bias is not necessarily predictive of superior adjuvanticity.


Subject(s)
Myeloid Differentiation Factor 88 , Toll-Like Receptor 4 , Adaptor Proteins, Vesicular Transport/metabolism , Animals , Dissociative Disorders , Lipopolysaccharides , Mice , Toll-Like Receptor 4/metabolism , Toll-Like Receptors
4.
Am J Addict ; 28(2): 119-126, 2019 02.
Article in English | MEDLINE | ID: mdl-30701618

ABSTRACT

BACKGROUND AND OBJECTIVE: Methamphetamine (MA) substance use disorder (SUD) does not have an efficacious pharmacotherapy. We developed a MA vaccine and investigated its potential to attenuate MA induced responses. METHODS: We examined a novel adjuvant, E6020, a Toll-like receptor-4 (TLR-4) agonist combined with tetanus-toxoid conjugated to succinyl-methamphetamine (TT-SMA) adsorbed on aluminum hydroxide (alum). Adult BALB/c female mice received the vaccine and booster injections at weeks 0, 3, and 6. The efficacy of the vaccine was assessed by the level and affinity of anti-MA antibodies elicited, its ability to attenuate MA induced locomotor activation and its reduction in the amount of MA entering the brains of vaccinated mice. RESULTS: The TT-SMA vaccine containing alum and E6020 adjuvant produced anti-MA antibodies with nanomolar affinities and showed threefold greater peak titer levels than without E6020 (700 vs 250 µg/ml). These antibodies significantly decreased MA-induced locomotor activation (p < .05), and reduced the brain (p < .005) MA levels following MA administration in actively immunized mice. CONCLUSIONS: Thus, this anti-MA vaccine formulated with E6020 demonstrated effective functional protection against behavioral disruptions induced by MA. SCIENTIFIC SIGNIFICANCE: Together, anti-MA vaccine showing a promising improvement in the efficacy of the vaccine that could be an effective candidate vaccine for methamphetamine use disorder (MUD). Furthermore, combinations of adjuvants may be a tool to design vaccines for MA dependence in humans. (Am J Addict 2019;XX:1-8).


Subject(s)
Aluminum Hydroxide/pharmacology , Amphetamine-Related Disorders/therapy , Methamphetamine/antagonists & inhibitors , Phospholipids/pharmacology , Tetanus Toxoid/pharmacology , Adjuvants, Immunologic/pharmacology , Animals , Biological Availability , Drug Combinations , Drug Monitoring/methods , Mice , Models, Animal , Toll-Like Receptor 4/agonists , Treatment Outcome
5.
Nature ; 560(7718): 350-354, 2018 08.
Article in English | MEDLINE | ID: mdl-30061620

ABSTRACT

Prized for their ability to rapidly generate chemical complexity by building new ring systems and stereocentres1, cycloaddition reactions have featured in numerous total syntheses2 and are a key component in the education of chemistry students3. Similarly, carbon-carbon (C-C) cross-coupling methods are integral to synthesis because of their programmability, modularity and reliability4. Within the area of drug discovery, an overreliance on cross-coupling has led to a disproportionate representation of flat architectures that are rich in carbon atoms with orbitals hybridized in an sp2 manner5. Despite the ability of cycloadditions to introduce multiple carbon sp3 centres in a single step, they are less used6. This is probably because of their lack of modularity, stemming from the idiosyncratic steric and electronic rules for each specific type of cycloaddition. Here we demonstrate a strategy for combining the optimal features of these two chemical transformations into one simple sequence, to enable the modular, enantioselective, scalable and programmable preparation of useful building blocks, natural products and lead scaffolds for drug discovery.


Subject(s)
Carbon/chemistry , Chemistry Techniques, Synthetic , Cycloaddition Reaction , Biological Products/chemical synthesis , Biological Products/chemistry , Drug Discovery
6.
J Appl Behav Anal ; 48(2): 233-56, 2015.
Article in English | MEDLINE | ID: mdl-25869079

ABSTRACT

Adults with autism spectrum disorder (ASD), who were interested in working as behavior technicians for young children with autism, participated in 2 experiments. Participants included 5 adults with Asperger syndrome or pervasive developmental disorder not otherwise specified, 19 to 23 years old, and 11 children with autism, 3 to 7 years old. In Experiment 1, training of the adults focused on the implementation of mand training via incidental teaching. Experiment 2 focused on teaching participants to use discrete-trial training (DTT) with children who exhibited problem behavior. Both experiments showed that behavioral skills training was effective for teaching the adult participants the behavioral procedures needed to teach children with autism. In addition, the children acquired skills as a result of training. Results of Experiment 2 further demonstrated that the DTT skills generalized across untrained targets and children. Social validity ratings suggested that some participants' teaching was indistinguishable from that of individuals without ASD.


Subject(s)
Autistic Disorder/therapy , Behavior Therapy/education , Child Development Disorders, Pervasive/psychology , Autism Spectrum Disorder/psychology , Autistic Disorder/psychology , Behavior Therapy/methods , Child , Child, Preschool , Female , Humans , Male , Young Adult
7.
Int J Pharm ; 486(1-2): 99-111, 2015.
Article in English | MEDLINE | ID: mdl-25794609

ABSTRACT

We describe the development, analytical characterization, stability and preclinical efficacy of AF04, a combination adjuvant comprising the synthetic toll-like receptor 4 (TLR4) agonist, E6020, formulated in AF03, a thermoreversible squalene emulsion. By using AF04 with the recombinant major outer membrane protein of Chlamydia trachomatis (Ct-MOMP) and with the recombinant surface glycoprotein gB from human cytomegalovirus (CMV-gB) as model antigens, we show that AF03 and E6020 can synergize to augment specific antibody and Th-1 cellular immune responses in mice. In terms of formulation, we observe that the method used to incorporate E6020 into AF03 affects its partition between the oil and water phases of the emulsion which in turn has a significant impact on the tolerability (IV pyrogenicity test in rabbits) of this novel adjuvant combination.


Subject(s)
Adjuvants, Immunologic , Bacterial Outer Membrane Proteins/immunology , Squalene , Toll-Like Receptor 4/agonists , Vaccines , Viral Proteins/immunology , Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/pharmacology , Animals , Antibodies, Bacterial/blood , Antibodies, Viral/blood , Antigens, Bacterial/immunology , Antigens, Viral/immunology , Cell Line , Chlamydia trachomatis , Cytokines/immunology , Cytomegalovirus , Dendritic Cells/drug effects , Dendritic Cells/immunology , Drug Design , Emulsions , Female , Glycoproteins/immunology , Humans , Immunoglobulin G/blood , Leukocytes, Mononuclear , Mice, Inbred C57BL , Rabbits , Squalene/chemistry , Squalene/pharmacology , Vaccines/chemistry , Vaccines/pharmacology
8.
J Appl Behav Anal ; 46(2): 465-78, 2013.
Article in English | MEDLINE | ID: mdl-24114161

ABSTRACT

We evaluated a behavioral skills training program for adults with autism spectrum disorder and mild or no intellectual disabilities who were interested in learning the skills used by behavior therapists to work with young children with autism and other developmental disabilities. Four adults, aged 21 to 30 years, participated. We trained each individually using verbal and written instructions, modeling, and role play with feedback to teach 2 basic skills to an adult who played the role of a young child with autism. We evaluated generalization of the discrete-trial training skills by having the participant (a) teach the adult confederate 2 additional targets that we had not included in training and (b) teach a new skill to a young child with autism. Results indicated that 3 of the 4 participants rapidly acquired discrete-trial training skills and that these skills generalized to new targets with the confederate adults and to teaching an actual child with autism.


Subject(s)
Autistic Disorder/therapy , Behavior Therapy/education , Child Development Disorders, Pervasive/psychology , Child Development Disorders, Pervasive/rehabilitation , Education , Vocational Education , Adult , Child, Preschool , Female , Generalization, Psychological , Humans , Male , Pilot Projects , Program Evaluation
9.
mBio ; 3(4)2012.
Article in English | MEDLINE | ID: mdl-22872782

ABSTRACT

UNLABELLED: Respiratory syncytial virus (RSV) is a leading cause of infant mortality worldwide. Toll-like receptor 4 (TLR4), a signaling receptor for structurally diverse microbe-associated molecular patterns, is activated by the RSV fusion (F) protein and by bacterial lipopolysaccharide (LPS) in a CD14-dependent manner. TLR4 signaling by LPS also requires the presence of an additional protein, MD-2. Thus, it is possible that F protein-mediated TLR4 activation relies on MD-2 as well, although this hypothesis has not been formally tested. LPS-free RSV F protein was found to activate NF-κB in HEK293T transfectants that express wild-type (WT) TLR4 and CD14, but only when MD-2 was coexpressed. These findings were confirmed by measuring F-protein-induced interleukin 1ß (IL-1ß) mRNA in WT versus MD-2(-/-) macrophages, where MD-2(-/-) macrophages failed to show IL-1ß expression upon F-protein treatment, in contrast to the WT. Both Rhodobacter sphaeroides LPS and synthetic E5564 (eritoran), LPS antagonists that inhibit TLR4 signaling by binding a hydrophobic pocket in MD-2, significantly reduced RSV F-protein-mediated TLR4 activity in HEK293T-TLR4-CD14-MD-2 transfectants in a dose-dependent manner, while TLR4-independent NF-κB activation by tumor necrosis factor alpha (TNF-α) was unaffected. In vitro coimmunoprecipitation studies confirmed a physical interaction between native RSV F protein and MD-2. Further, we demonstrated that the N-terminal domain of the F1 segment of RSV F protein interacts with MD-2. These data provide new insights into the importance of MD-2 in RSV F-protein-mediated TLR4 activation. Thus, targeting the interaction between MD-2 and RSV F protein may potentially lead to novel therapeutic approaches to help control RSV-induced inflammation and pathology. IMPORTANCE: This study shows for the first time that the fusion (F) protein of respiratory syncytial virus (RSV), a major cause of bronchiolitis and death, particularly in infants and young children, physically interacts with the Toll-like receptor 4 (TLR4) coreceptor, MD-2, through its N-terminal domain. We show that F protein-induced TLR4 activation can be blocked by lipid A analog antagonists. This observation provides a strong experimental rationale for testing such antagonists in animal models of RSV infection for potential use in people.


Subject(s)
Down-Regulation , Lipid A/analogs & derivatives , Lymphocyte Antigen 96/metabolism , Respiratory Syncytial Virus Infections/metabolism , Respiratory Syncytial Viruses/metabolism , Signal Transduction , Toll-Like Receptor 4/immunology , Viral Fusion Proteins/metabolism , Animals , Cell Line , Humans , Lipid A/metabolism , Lipopolysaccharides/metabolism , Lymphocyte Antigen 96/genetics , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/microbiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Protein Binding , Respiratory Syncytial Virus Infections/genetics , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus Infections/microbiology , Respiratory Syncytial Viruses/genetics , Respiratory Syncytial Viruses/immunology , Toll-Like Receptor 4/antagonists & inhibitors , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism , Viral Fusion Proteins/genetics
10.
Hum Vaccin Immunother ; 8(4): 486-90, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22832252

ABSTRACT

The inclusion of a potent TLR4 immune potentiator to a recombinant antigen vaccine formulation enhances both the magnitude and the breadth of the engendered immune response. One such immune potentiator (TLR4 agonist E6020) was evaluated with recombinant Men B antigens delivered in MF59 sub-micron adjuvant emulsion. The ability of this formulation to enhance serum antibody and bactercidal titers was investigated. The co-delivery of E6020 within MF59 enhanced both the serum and bactericidal titers for Men B antigens and for Men B antigens combined with Men ACWY-CRM conjugate vaccine. The delivery of TLR4 agonist within MF59 emulsion oil droplets leads to a more potent response in comparison to the TLR4 when admixed with MF59 emulsion.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Meningococcal Vaccines/administration & dosage , Meningococcal Vaccines/immunology , Polysorbates/administration & dosage , Squalene/administration & dosage , Toll-Like Receptor 4/agonists , Animals , Antibodies, Bacterial/blood , Blood Bactericidal Activity , Female , Mice , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology
11.
Cancer Immunol Immunother ; 61(1): 49-61, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21842208

ABSTRACT

Toll-like receptors are potent activators of the innate immune system and generate signals leading to the initiation of the adaptive immune response that can be utilized for therapeutic purposes. We tested the hypothesis that combined treatment with a Toll-like receptor agonist and an antitumor monoclonal antibody is effective and induces host-protective antitumor immunity. C57BL/6 human mutated HER2 (hmHER2) transgenic mice that constitutively express kinase-deficient human HER2 under control of the CMV promoter were established. These mice demonstrate immunological tolerance to D5-HER2, a syngeneic human HER2-expressing melanoma cell line. This human HER2-tolerant model offers the potential to serve as a preclinical model to test both antibody therapy and the immunization potential of human HER2-targeted therapeutics. Here, we show that E6020, a Toll-like receptor-4 (TLR4) agonist effectively boosted the antitumor efficacy of the monoclonal antibody trastuzumab in immunodeficient C57BL/6 SCID mice as well as in C57BL/6 hmHER2 transgenic mice. E6020 and trastuzumab co-treatment resulted in significantly greater inhibition of tumor growth than was observed with either agent individually. Furthermore, mice treated with the combination of trastuzumab and the TLR4 agonist were protected against rechallenge with human HER2-transfected tumor cells in hmHER2 transgenic mouse strains. These findings suggest that combined treatment with trastuzumab and a TLR4 agonist not only promotes direct antitumor effects but also induces a host-protective human HER2-directed adaptive immune response, indicative of a memory response. These data provide an immunological rationale for testing TLR4 agonists in combination with antibody therapy in patients with cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Melanoma, Experimental/drug therapy , Toll-Like Receptor 4/agonists , Animals , Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/immunology , Cell Line, Tumor , Humans , Immunohistochemistry , Melanoma, Experimental/enzymology , Melanoma, Experimental/genetics , Melanoma, Experimental/immunology , Mice , Mice, Inbred C57BL , Mice, SCID , Mice, Transgenic , Receptor, ErbB-2/biosynthesis , Receptor, ErbB-2/genetics , Receptor, ErbB-2/immunology , Toll-Like Receptor 4/immunology , Trastuzumab
12.
Pharm Res ; 26(6): 1477-85, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19255727

ABSTRACT

PURPOSE: The effectiveness of vaccines depends on the age and immunocompetence of the vaccinee. Conventional non-adjuvanted influenza vaccines are suboptimal in the elderly and vaccines with improved ability to prevent influenza are required. The TLR4 agonist E6020, either given alone or co-delivered with MF59, was evaluated and compared to MF59 and the TLR9 agonist CpG. Its ability to enhance antibody titres and to modulate the quality of the immune response to a subunit influenza vaccine was investigated. METHODS: Mice were immunized with either antigens alone, with MF59 or with the TLR agonists alone, or with a combination thereof. Serum samples were assayed for IgG antibody titres and hemagglutination inhibition (HI) titres. Th1/Th2 type responses were determined by titrating IgG subclasses in serum samples and by T-cell cytokine responses in splenocytes. RESULTS: MF59 was the best single adjuvant inducing HI and T-cell responses in comparison to all alternatives. The co-delivery of E6020 or CpG with MF59 did not further increase antibody titres however shifted towards a more Th1 based immune response. CONCLUSION: Combining adjuvants like E6020 and MF59 allowed a finer tuning of the immune response towards a particular Th bias, thus have significant implications for the development of improved influenza vaccines.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Antibodies, Viral/immunology , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H3N2 Subtype/immunology , Influenza Vaccines/administration & dosage , Polysorbates/administration & dosage , Squalene/administration & dosage , Toll-Like Receptor 4/agonists , Animals , Antibodies, Viral/blood , Cytokines/immunology , Drug Delivery Systems/methods , Female , Hemagglutination Inhibition Tests , Immunization , Immunoglobulin G/immunology , Influenza Vaccines/immunology , Mice , Mice, Inbred BALB C , Squalene/immunology , Th1 Cells/drug effects , Th1 Cells/immunology , Th2 Cells/drug effects , Th2 Cells/immunology
13.
Med Chem ; 4(6): 520-5, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18991733

ABSTRACT

Although hemoglobin (Hb) is mainly present in the cytoplasm of erythrocytes (red blood cells), lower concentrations of pure, cell-free Hb are released permanently into the circulation due to an inherent intravascular hemolytic disruption of erythrocytes. Previously it was shown that the interaction of Hb with bacterial endotoxins (lipopolysaccharides, LPS) results in a significant increase of the biological activity of LPS. There is clear evidence that the enhancement of the biological activity of LPS by Hb is connected with a disaggregation of LPS. From these findings one questions whether the property to enhance the biological activity of endotoxin, in most cases proven by the ability to increase the cytokine (tumor-necrosis-factor-alpha, interleukins) production in human mononuclear cells, is restricted to bacterial endotoxin or is a more general principle in nature. To elucidate this question, we investigated the interaction of various synthetic and natural virulence (pathogenicity) factors with hemoglobin of human or sheep origin. In addition to enterobacterial R-type LPS a synthetic bacterial lipopeptide and synthetic phospholipid-like structures mimicking the lipid A portion of LPS were analysed. Furthermore, we also tested endotoxically inactive LPS and lipid A compounds such as those from Chlamydia trachomatis. We found that the observations made for endotoxically active form of LPS can be generalized for the other synthetic and natural virulence factors: In every case, the cytokine-production induced by them is increased by the addition of Hb. This biological property of Hb is connected with its physical property to convert the aggregate structures of the virulence factors into one with cubic symmetry, accompanied with a considerable reduction of the size and number of the original aggregates.


Subject(s)
Hemoglobins/pharmacology , Virulence Factors/pharmacology , Animals , Carbohydrates/chemistry , Cytokines/biosynthesis , Freeze Fracturing , Humans , In Vitro Techniques , Lipids/chemistry , Lipopolysaccharides/chemistry , Lipopolysaccharides/pharmacology , Monocytes/metabolism , Salmonella/chemistry , Sheep , Spectroscopy, Fourier Transform Infrared , Structure-Activity Relationship , Temperature , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/genetics , Virulence Factors/chemistry , X-Ray Diffraction
14.
Expert Rev Vaccines ; 6(5): 773-84, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17931157

ABSTRACT

Safe and cost-effective adjuvants are a critical component to enhance the efficacy of subunit vaccines. Studies have demonstrated that modified natural lipid As derived from enterobacterial lipopolysaccharides, which are agonists of Toll-like receptor 4, are beneficial to vaccine performance. The synthetic phospholipid dimer, E6020, mimics the physicochemical and biological properties of many of the natural lipid As derived from gram-negative bacteria. Similar to its natural counterparts, E6020, which was discovered and developed by Eisai, agonizes Toll-like receptor 4, albeit in an attenuated fashion, eliciting an immunostimulatory response that is conducive to use as a vaccine adjuvant. The derivation of E6020, along with physicochemical properties and in vitro and in vivo studies of immunostimulation and adjuvant activity, are reviewed as a background to its imminent assessment in the clinic.


Subject(s)
Adjuvants, Immunologic/chemistry , Phospholipids/chemistry , Toll-Like Receptor 4/chemistry , Vaccines/chemistry , Adjuvants, Immunologic/administration & dosage , Animals , Humans , Phospholipids/administration & dosage , Toll-Like Receptor 4/administration & dosage , Vaccines/administration & dosage
15.
Clin Vaccine Immunol ; 14(11): 1499-504, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17715328

ABSTRACT

The development of new protein subunit vaccines has stimulated the search for improved adjuvants to replace traditional aluminum-containing products. We investigated the adjuvant effects of a synthetic Toll-like receptor 4 (TLR4) agonist on vaccine efficacy in an experimental model of toxic shock syndrome. The TLR4 agonist E6020 has a simplified structure consisting of a hexa-acylated acyclic backbone. The vaccine examined is a recombinantly attenuated form of staphylococcal enterotoxin B (STEBVax). Using cells stably transfected with TLRs, E6020 transduced signals only through TLR4, suggesting monospecificity, while Escherichia coli 055:B5 lipopolysaccharide activated both the TLR2/6 heterodimer and TLR4. Coadministration of E6020 with STEBVax, by the intramuscular or intranasal route, induced significant levels of immunoglobulin G (IgG) in BALB/c mice. Further, increased IgG production resulted from the combination of E6020 with aluminum hydroxide adjuvant (AH). The antibody response to the vaccine coadministered with E6020 was a mixed Th1/Th2 response, as opposed to the Th2-biased response obtained with AH. Mice vaccinated with STEBVax coadministered with AH, TLR4 agonists, or a combination of both adjuvants were protected from toxic shock. Our data demonstrate the effectiveness of the synthetic TLR4 agonist E6020 as an alternative adjuvant for protein subunit vaccines that may also be used in combination with traditional aluminum-containing adjuvants.


Subject(s)
Adjuvants, Immunologic , Bacterial Vaccines/immunology , Enterotoxins/immunology , Shock, Septic/prevention & control , Staphylococcus aureus/immunology , Toll-Like Receptor 4/agonists , Aluminum Hydroxide/immunology , Aluminum Hydroxide/pharmacology , Animals , Cytokines/biosynthesis , Cytokines/immunology , Immunoglobulins/blood , Lipopolysaccharides/immunology , Male , Mice , Mice, Inbred BALB C , Models, Animal , Shock, Septic/immunology , Shock, Septic/microbiology , Signal Transduction , Th1 Cells/immunology , Th2 Cells/immunology , Toll-Like Receptor 2/immunology , Toll-Like Receptor 4/immunology , Toll-Like Receptor 6/immunology
16.
Bioorg Med Chem Lett ; 15(24): 5494-8, 2005 Dec 15.
Article in English | MEDLINE | ID: mdl-16236498

ABSTRACT

Novel synthetic phospholipid compound 1 was discovered to be an antagonist of human toll-like receptor 2 (TLR2) signaling. In a preliminary SAR campaign we synthesized several analogues of 1 and found that considerable structural changes could be made without loss of TLR2 antagonistic activity.


Subject(s)
Phospholipids/chemical synthesis , Phospholipids/pharmacology , Toll-Like Receptor 2/antagonists & inhibitors , Humans , Indicators and Reagents , Kinetics , Models, Molecular , Stereoisomerism , Structure-Activity Relationship
17.
Shock ; 23(4): 365-70, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15803061

ABSTRACT

Endotoxin tolerance provides protection against mortality under various conditions of stress. However, the induction of endotoxin tolerance thus far has no clinical application because of endotoxin toxicity and the excessive immune suppression that follows the tolerance induction. In this study, we examined whether a novel, synthetic lipopolysaccharide (LPS) receptor agonist, ER-803058 (ER) can induce endotoxin tolerance with accompanying low toxicity. The stimulative effects of ER on tumor necrosis factor (TNF)-alpha production from RAW264 cells were 50% to 70% lower than those of the corresponding quantities of LPS. ER pretreatment also diminished TNF-alpha secretion induced by a subsequent LPS shock. However, the degree of desensitization with ER pretreatment (10 ng/mL, 55.5% +/- 6.7%; 100 ng/mL, 42.3 +/- 4.9%) was modest in contrast with that measured for the corresponding LPS pretreatment (10 ng/mL, 36.7% +/- 3.7%; 100 ng/mL, 20.0% +/- 3.6%). The minimum in vivo dose (0.02 mg/kg/body weight) of ER-induced negligible production of TNF-alpha and interleukin (IL)-6 in rats, and resulted in a modest endotoxin tolerance with respect to TNF-alpha secretion. Although the plasma TNF-alpha level after ER pretreatment was decreased (48.2% +/- 1.1%), the suppression was not statistically significant. Interestingly, even this minimal quantity of ER pretreatment evoked a dramatic improvement in survival (90% survival) against administration of a lethal dose of LPS, which is inconsistent with the modest TNF-alpha suppression. Furthermore, ER pretreatment preserved normal plasma albumin levels and prevented the increase of plasma blood urea nitrogen levels seen with LPS. These results indicate that pretreatment with ER can effectively induce endotoxin tolerance, with a consequent improvement in mortality without toxicity and without subsequent excessive immunosuppression.


Subject(s)
Endotoxemia/drug therapy , Endotoxins/toxicity , Immune System/drug effects , Lipopolysaccharide Receptors/metabolism , Albumins/biosynthesis , Albumins/metabolism , Animals , Blood Urea Nitrogen , Body Weight , Cell Line , Cytokines/blood , Cytokines/metabolism , Dose-Response Relationship, Drug , Endotoxins/metabolism , Immunosuppressive Agents/pharmacology , Interferon-gamma/metabolism , Interleukin-10/metabolism , Interleukin-6/metabolism , Lipopolysaccharides/metabolism , Lipopolysaccharides/pharmacology , Macrophages/metabolism , Male , Mice , Rats , Rats, Wistar , Time Factors , Tumor Necrosis Factor-alpha/metabolism
19.
Curr Top Med Chem ; 4(11): 1147-71, 2004.
Article in English | MEDLINE | ID: mdl-15279606

ABSTRACT

Endotoxin, from the outer membrane of Gram-negative bacteria, has been implicated as the etiological agent of a variety of pathologies ranging from relatively mild (fever) to lethal (septic shock, organ failure, and death). While endotoxin (also known as lipopolysaccharide or LPS) is a complex heterogeneous molecule, the toxic portion of LPS (the lipid A portion) is relatively similar across a wide variety of pathogenic strains of bacteria, making this molecule an attractive target for the development of an LPS antagonist. Research over the past fifteen years focused on the design of various lipid A analogs including monosaccharide, acyclic and disaccharide compounds has lead to the development of E5564, an advanced, unique and highly potent LPS antagonist. E5564 is a stable, pure LPS antagonist that is selective against endotoxin-mediated activation of immune cells in vitro and in animal models. In Phase I clinical trials, we have developed an ex vivo endotoxin antagonism assay that has provided results on pharmacodynamic activity of E5564 in addition to the more typical safety and pharmacokinetic evaluations. Results from these assays have been reinforced by analysis of in vivo antagonistic activity using a human endotoxemia model. Results from all of these studies indicate that E5564 is an effective in vivo antagonist of endotoxin, and may prove to be of benefit in a variety of endotoxin-mediated diseases. This review discusses the evolution of synthetic LPS antagonists with emphasis on the SAR and development of E5564 and its precursors.


Subject(s)
Drug Design , Endotoxins/antagonists & inhibitors , Endotoxins/metabolism , Membrane Glycoproteins/antagonists & inhibitors , Receptors, Cell Surface/antagonists & inhibitors , Sepsis/drug therapy , Animals , Endotoxins/chemistry , Endotoxins/pharmacology , Humans , Lipopolysaccharides/antagonists & inhibitors , Lipopolysaccharides/chemistry , Lipopolysaccharides/metabolism , Lipopolysaccharides/pharmacology , Membrane Glycoproteins/metabolism , Receptors, Cell Surface/metabolism , Toll-Like Receptor 4 , Toll-Like Receptors
20.
Antimicrob Agents Chemother ; 47(9): 2796-803, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12936976

ABSTRACT

The objective of this study was to determine the distribution profile of the novel endotoxin antagonist E5564 in plasma obtained from fasted human subjects with various lipid concentrations. Radiolabeled E5564 at 1 microM was incubated in fasted plasma from seven human subjects with various total cholesterol (TC) and triglyceride (TG) concentrations for 0.5 to 6 h at 37 degrees C. Following these incubations, plasma samples were separated into their lipoprotein and lipoprotein-deficient fractions by ultracentrifugation and were assayed for E5564 radioactivity. TC, TG, and protein concentrations in each fraction were determined by enzymatic assays. Lipoprotein surface charge within control and phosphatidylinositol-treated plasma and E5564's influence on cholesteryl ester transfer protein (CETP) transfer activity were also determined. We observed that the majority of E5564 was recovered in the high-density lipoprotein (HDL) fraction. We further observed that incubation in plasma with increased levels of TG-rich lipoprotein (TRL) lipid (TC and TG) concentrations resulted in a significant increase in the percentage of E5564 recovered in the TRL fraction. In further experiments, E5564 was preincubated in human TRL. Then, these mixtures were incubated in hypolipidemic human plasma for 0.5 and 6 h at 37 degrees C. Preincubation of E5564 in purified TRL prior to incubation in human plasma resulted in a significant decrease in the percentage of drug recovered in the HDL fraction and an increase in the percentage of drug recovered in the TRL and low-density lipoprotein fractions. These findings suggest that the majority of the drug binds to HDLs. Preincubation of E5564 in TRL prior to incubation in normolipidemic plasma significantly decreased the percentage of drug recovered in the HDL fraction. Modifications to the lipoprotein negative charge did not alter the E5564 concentration in the HDL fraction. In addition, E5564 does not influence CETP-mediated transfer activity. Information from these studies could be used to help identify the possible components of lipoproteins which influence the interaction of E5564 with specific lipoprotein particles.


Subject(s)
Endotoxins/antagonists & inhibitors , Glycoproteins , Lipid A/analogs & derivatives , Lipid A/pharmacokinetics , Lipoproteins, HDL/metabolism , Lipoproteins, LDL/metabolism , Triglycerides/metabolism , Animals , Carrier Proteins/metabolism , Cholesterol/blood , Cholesterol Ester Transfer Proteins , Humans , Lipid A/blood , Protein Binding , Rabbits , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...